Toutes les études
RecrutementPHASE2INTERVENTIONNEL

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

This research study is looking into a new medicine called LY4005130 for adults with severe alopecia areata, a condition where people experience significant hair loss. The main goals are to find out how effective this medicine is at helping hair regrow compared to a 'dummy' treatment (placebo), and to understand any side effects it might cause. Researchers will also take blood tests to see how the body handles the medicine and how the medicine affects the body. The medicine will be given directly into a vein in the arm. The study will last for about 48 weeks, which is roughly 11-12 months, including an initial checking period.

En un coup d'œil

Statut
Recrutement
Phase
PHASE2
Sponsor
Eli Lilly et Compagnie
Objectif d'inscription
65
Démarrer
14 Apr 2026
Achèvement estimé
01 Oct 2027

De quoi parle cette étude ?

Alopecia areata is a condition where your immune system mistakenly attacks your hair follicles, leading to hair loss. This study is exploring a potential new treatment, called LY4005130, for people with a severe form of this condition. The aim is to see if this new medicine can help people grow their hair back, and how it compares to not receiving the active medicine.

Researchers will carefully compare the new medicine to a 'placebo', which looks exactly like the medicine but contains no active ingredients. This is a standard way to test new treatments, as it helps determine if any changes or improvements are truly due to the medicine itself rather than other factors. They will also be closely monitoring participants for any side effects to understand how well the medicine is tolerated by the body. Blood tests will be part of the study to help us understand how your body uses and responds to the medicine.

Understanding how new treatments work and what their side effects might be is really important for developing better ways to help people with alopecia areata. This study is a stepping stone in that process, providing valuable information that could one day lead to approved medicines to help manage this condition.

Points clés

  • Tests a new medicine (LY4005130) for severe alopecia areata.
  • Compares the medicine to a dummy treatment (placebo).
  • Aims to understand effectiveness and potential side effects.
  • Medicine given into a vein; involves regular clinic visits.
  • Total study duration is about 48 weeks.
  • Suitable for adults aged 18-50 with specific hair loss criteria.

Qui peut être éligible ?

This study is looking for adults aged between 18 and 50 years old. To join, you must have severe alopecia areata, meaning you've lost hair on at least half, but not more than 90%, of your scalp. Your current hair loss episode must have lasted for at least 6 months but no longer than 4 years, and your hair shouldn't have grown back much on its own in the last six months.

You cannot join this study if you have a different type of hair loss, or if you are currently using other alopecia areata treatments or planning to use them during the study. It's also not suitable for you if you've had certain other treatments in the past, like specific 'JAK inhibitors' medicines, or if you've had major surgery recently or need one soon.

Also, if you have other serious health conditions that need frequent hospital visits or strong medicines, or specific heart, lung, stomach, or other disorders, this study might not be safe for you. The study team will review your full medical history to make sure it's safe for you to take part.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous entre 18 et 50 ans ?
  2. Have you lost more than half, but not all, of your scalp hair from alopecia areata?
  3. Has your current hair loss lasted for at least 6 months but no more than 4 years?
  4. Have you avoided specific hair loss treatments like JAK inhibitors in the past?
  5. Are you generally in good health without other serious medical conditions?
  6. Are you able to commit to regular clinic visits for about 48 weeks?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, the study medicine, LY4005130, will be given to you directly into a vein in your arm (this is called an intravenous or IV infusion). You will receive either the active medicine or a placebo (a dummy medicine) – you won't know which one you are getting. During the study, you will have several appointments at the study clinic. These visits will involve various checks, such as measuring your hair loss, physical examinations, and taking blood samples. These blood tests help us understand how the medicine is working and how your body is reacting to it. The entire study, including the initial checks to see if you can join, will last for about 48 weeks, which is nearly a year.

Risques et avantages potentiels

Taking part in a clinical trial offers the chance to access a new treatment that isn't widely available yet, which might help your hair regrow. However, like all medicines, LY4005130 could have side effects, and we don't yet know all of them. Being in the study also means regular hospital visits, blood tests, and scans. You will be closely monitored for your safety and well-being throughout, and you are free to change your mind and withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (30)

  • Center For Dermatology Clinical Research, Inc.
    Code postal vérifié
    Fremont, United States· Recrutement
  • Northridge Clinical Trials
    Code postal vérifié
    Northridge, United States· Recrutement
  • Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
    Code postal vérifié
    Santa Clarita, United States· Recrutement
  • Health Clinical Research, LLC
    Code postal vérifié
    Cutler Bay, United States· Recrutement
  • Hôpital Brigham and Women's
    Code postal vérifié
    Boston, États-Unis· Recrutement
  • Revival Research Institute, LLC
    Code postal vérifié
    Troy, États-Unis· Recrutement
  • Stracskin
    Code postal vérifié
    Portsmouth, United States· Recrutement
  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
    Code postal vérifié
    San Antonio, United States· Recrutement
  • Jordan Valley Dermatology & Research Center
    Code postal vérifié
    South Jordan, United States· Recrutement
  • Kelowna Health and Memory Centre
    Code postal vérifié
    Kelowna, Canada· Recrutement
  • Ryan Clinical Research Inc.
    Code postal vérifié
    Newmarket, Canada· Recrutement
  • Dar Clinical Research - Ottawa - Hunt Club Road
    Code postal vérifié
    Ottawa, Canada· Recrutement

Questions fréquentes

Qu'est-ce que l'alopécie areata ?

Alopecia areata is an autoimmune condition where your immune system mistakenly attacks your hair follicles, causing hair to fall out in patches or, in severe cases, all over the body.

What is LY4005130?

LY4005130 is the name of the new experimental medicine being tested in this study for severe alopecia areata.

What does 'placebo' mean in a study?

A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active ingredients. It helps researchers compare if the new medicine is actually effective.

How will I receive the study medicine?

The study medicine will be given to you directly into a vein in your arm, similar to getting a drip.

How long will the study last if I join?

If you join this study, it will last for about 48 weeks in total, which is nearly a year.

Comment en savoir plus

Questions sur les essais ou questions de participation : 1-877-CTLILLY (1-877-285-4559) ou

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study of LY4005130 in Adult Participants With Severe Alope… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.